Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Spondyloarthritis: update on pathogenesis and management
JD Reveille, FC Arnett - The American journal of medicine, 2005 - Elsevier
A great deal of progress has occurred in the past few years in elucidating the causes and
designing new treatments for ankylosing spondylitis and other types of spondyloarthritis. In …
designing new treatments for ankylosing spondylitis and other types of spondyloarthritis. In …
Cytokines and chemokines in uveitis–Is there a correlation with clinical phenotype?
KGJ Ooi, G Galatowicz, VL Calder… - Clinical medicine & …, 2006 - clinmedres.org
Uveitis is a general term for intraocular inflammation and includes a large number of clinical
phenotypes. As a group of disorders, it is responsible for 10% of all registered blind patients …
phenotypes. As a group of disorders, it is responsible for 10% of all registered blind patients …
Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor α in two patients with early …
Objective: To characterise the immunohistological features of sacroiliitis in ankylosing
spondylitis (AS) at different disease stages. Methods: Biopsy samples from sacroiliac joints …
spondylitis (AS) at different disease stages. Methods: Biopsy samples from sacroiliac joints …
Pathogenesis of ankylosing spondylitis and reactive arthritis
Current Opinion in Rheumatology Log in or Register Subscribe to journalSubscribe Get new
issue alertsGet alerts Secondary Logo Journal Logo Advanced Search Toggle navigation …
issue alertsGet alerts Secondary Logo Journal Logo Advanced Search Toggle navigation …
Association of cytokine and matrix metalloproteinase profiles with disease activity and function in ankylosing spondylitis
Introduction The pathology of ankylosing spondylitis (AS) suggests that certain cytokines
and matrix metalloproteinases (MMPs) might provide useful markers of disease activity …
and matrix metalloproteinases (MMPs) might provide useful markers of disease activity …
The genetic basis of ankylosing spondylitis
JD Reveille - Current opinion in rheumatology, 2006 - journals.lww.com
Nearly half of the susceptibility to ankylosing spondylitis is provided by major
histocompatibility complex genes. Non-major histocompatibility complex genes, most …
histocompatibility complex genes. Non-major histocompatibility complex genes, most …
The effects of nanocurcumin on Treg cell responses and treatment of ankylosing spondylitis patients: A randomized, double‐blind, placebo‐controlled clinical trial
Aim Ankylosing spondylitis (AS) is an inflammatory rheumatic disease with increased bone
mass in the main sites of inflammation. Regulatory T (Treg) cells have been reported to …
mass in the main sites of inflammation. Regulatory T (Treg) cells have been reported to …
IL-33 signaling protects from murine oxazolone colitis by supporting intestinal epithelial function
A Waddell, JE Vallance, PD Moore… - Inflammatory bowel …, 2015 - academic.oup.com
Background IL-33, a member of the IL-1 cytokine family that signals through ST2, is
upregulated in ulcerative colitis (UC); however, the role of IL-33 in colitis remains unclear. IL …
upregulated in ulcerative colitis (UC); however, the role of IL-33 in colitis remains unclear. IL …
The pathogenesis of ankylosing spondylitis
✓ Ankylosing spondylitis (AS) is a chronic inflammatory disease that can cause significant
functional complications by affecting the sacroiliac joints and axial skeleton. Despite a …
functional complications by affecting the sacroiliac joints and axial skeleton. Despite a …
Inhibition of complement retards ankylosing spondylitis progression
C Yang, P Ding, Q Wang, L Zhang, X Zhang, J Zhao… - Scientific reports, 2016 - nature.com
Ankylosing spondylitis (AS) is a chronic axial spondyloarthritis (SpA) resulting in back pain
and progressive spinal ankyloses. Currently, there are no effective therapeutics targeting AS …
and progressive spinal ankyloses. Currently, there are no effective therapeutics targeting AS …